Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors

Drug Safety

Volumn 31, Issue 7, 2008, Pages 587-596

  Molden, Espen ^a   Skovlund, Eva ^a   Braathen, Pia ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b Alliance Apotek   (Norway)

Author keywords

Atorvastatin, adverse reactions; Atorvastatin, drug interactions; Cytochrome P450 inhibitors, drug interactions; Drug interactions; Simvastatin, adverse reactions; Simvastatin, drug interactions

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; HEALTH CARE PERSONNEL; HUMAN; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK MANAGEMENT;

ADULT; AGED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MUSCULAR DISEASES; PYRROLES; RISK MANAGEMENT; SIMVASTATIN;

EID: 45549089673     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831070-00004     Document Type: Article

References (47)

1. Bottorff MB. Statin safety and drug interactions: clinical impli-cations. Am J Cardiol 2006; 97: 27C-31C
2. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63
3. Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9
4. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57
5. Law M, Rudnicka AR. Statin safety: a systematic review. Am Cardiol 2006; 97: 52C-60C
6. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-7
7. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26
8. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81
9. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295-7
10. Itakura H, Vaughn D, Haller DG, et al. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer [letter]. J Urol 2003; 169: 613
11. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65
12. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41
13. Saliba WR, Elias M. Severe myopathy induced by the co- administration of simvastatin and itraconazole [letter]. Eur Intern Med 2005; 16: 305
14. Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37: 1032-5
15. Kahri J, Valkonen M, Backlund T, et al. Rhabdomyolysis in patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005; 60: 905-7
16. Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-74
17. Lewin 3rd JJ, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002; 36: 1546-9
18. Kanathur N, Mathai MG, Byrd Jr RP, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-41
19. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82
20. Becquemont L, Neuvonen M, Verstuyft C, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 2007; 81: 679-84
21. Roten L, Schoenenberger RA, Krahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38: 978-81
22. Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006; 40: 753-7
23. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ ritonavir in a patient with HIV. AIDS Patient Care STDS 2003; 17: 207-10
24. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-77
25. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmaco-kinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-50
26. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002; 35: e111-2
27. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140-6
28. Molden E, Andersson K. Simvastatin-associated rhabdomyolysis after co-administration of macrolide antibiotics in two patients. Pharmacotherapy 2007; 27: 603-7
29. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 2002; 42: 444-9
30. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37: 808-11
31. Siedlik PH, Olson SC, Yang BB, et al. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501-4
32. Rätz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28: 263-75
33. Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 2006; 29: 1061-7
34. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95
35. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97: 61C-8C
36. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31
37. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
38. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18 Suppl. 1: S71-6
39. von Rosensteil NA, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 1995; 13: 105-22
40. Backman JT, Olkkola KT, Neuvonen PJ. Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther 1995; 33: 356-9
41. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994; 11: 921-4
42. Katoh M, Nakajima M, Shimada N, et al. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55: 843-52
43. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-30
44. Zocor (simvastatin) prescribing information [online]. Available from URL: http://www.zocor.com/zocor/shared/documents/english/pi.pdf [Accessed 2007 Jul 10]
45. Lipitor (atorvastatin) prescribing information [online]. Available from URL: http://www.lipitor.com/content/LipitorPI.pdf [Accessed 2007 Jul 10]
46. Molden E, Westergren T. Interaction risk with statin switch [in Norwegian]. Tidsskr Nor Laegeforen 2007; 127: 428-31
47. Molden E, Garcia BH, Braathen P, et al. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice: a retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 2005; 61: 119-25